PharmaMar
PharmaMar
Explore linked clinical trials.8 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Interest of Post-operative Chemotherapy in Patients With Localised Uterine Leiomyosarcoma Suspected of Having a High Risk of Recurrence Based on a Biological Test Performed on the Tumour | Leiomyosarcoma Uterus | Recruiting | Phase 2 | 2026-09-29 | NCT06524583 | |
| Study of PM54 in Combination With Cytotoxic and Targeted Agents in Adult Participants With Advanced Malignancies | Advanced Solid Tumor | Not yet recruiting | Phase 1 / Phase 2 | 2026-09-24 | NCT07839819 | |
| Study of PM54 in Combination With Immunotherapy in Adult Participants With Advanced Malignancies | Advanced Malignancies | Recruiting | Phase 1 / Phase 2 | 2026-07-30 | NCT07644039 | |
| Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo) | Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, leiomyosarcoma, myomatous neoplasm, neoplasm, sarcoma | Active, not recruiting | Phase 3 | 2026-06-18 | NCT06088290 | |
| Study on Trabectedin in Advanced Rearranged Mesenchymal Chondrosarcoma | Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, chondrosarcoma, connective tissue neoplasm, mesenchymal chondrosarcoma, neoplasm, sarcoma | Recruiting | Phase 2 | 2026-03-27 | NCT04305548 | |
| Trial in Patients With Metastatic or Locally Advanced Leiomyosarcoma | Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, neoplasm, ovary leiomyosarcoma, sarcoma | Recruiting | Phase 2 | 2026-03-25 | NCT04383119 | |
| Clinical Trial of PM54 in Advanced Solid Tumors Patients. | Advanced Solid Tumor | Recruiting | Phase 1 | 2025-09-24 | NCT05841563 | |
| PM534 Administered Intravenously to Patients With Advanced Solid Tumors | Patients With Advanced Solid Tumors | Recruiting | Phase 1 | 2025-08-22 | NCT05835609 |